Triple-negative breast cancer trials in China

In China 133 Also abroad 423

133 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
Where
Beijing, Shanghai
Age
18 years to 75 years
People
400
Run by
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07111832
No phaseTaking people
Psychological State, Immunotherapy Response, and Multi-Omics Signatures in TNBC
Where
Shanghai
Age
18 years to 70 years
People
120
Run by
Fudan University
See details and how to joinNCT07290153
Phase 3Taking people
Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer
Where
Guangzhou
Age
18 years to 70 years
People
228
Run by
Sun Yat-Sen University Cancer Center
See details and how to joinNCT04722978
Phase 2Taking people
Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC
Where
Zhengzhou
Age
18 years to 65 years
People
64
Run by
Henan Cancer Hospital
See details and how to joinNCT06817525
Phase 2Taking people
The Optimal Radioimmunotherapy Combinations for Advanced TNBC
Where
Guangzhou
People
60
Run by
Sun Yat-sen University
See details and how to joinNCT06735131
Phase 1/2Taking people
Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors
Where
Jinan
Age
18 years and over
People
156
Run by
Mainline Biosciences (Shanghai) Co., Ltd
See details and how to joinNCT06840821
Phase 2Not yet taking people in China
Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)
Where
Guangzhou
Age
18 years and over
People
29
Run by
Sun Yat-sen University
See details and how to joinNCT07255612
Phase 1Taking people
A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC
Where
Xi'an
Age
18 years to 70 years
People
30
Run by
Xijing Hospital
See details and how to joinNCT07178171
Phase 2Not yet taking people in China
A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)
Where
Yantai
Age
18 years to 75 years
People
52
Run by
Yantai Yuhuangding Hospital
See details and how to joinNCT07054242
Phase 3Taking people
A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Where
Beijing
Age
18 years and over
People
504
Run by
Qilu Pharmaceutical Co., Ltd.
See details and how to joinNCT06732323
Phase 2Taking people
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer
Where
Shijiazhuang
Age
18 years to 70 years
People
520
Run by
Hebei Medical University Fourth Hospital
See details and how to joinNCT04138719
Phase 2Taking people
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer
Where
Shijiazhuang
Age
18 years to 70 years
People
414
Run by
Hebei Medical University Fourth Hospital
See details and how to joinNCT04159142
Phase 2Not yet taking people in China
A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC
Where
Guangzhou
Age
18 years and over
People
150
Run by
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT07040644
Phase 2Not yet taking people in China
Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer
Where
Tianjin
Age
18 years and over
People
47
Run by
Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07153965
Phase 1/2Not yet taking people in China
Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer
Where
Tianjin
Age
18 years and over
People
59
Run by
Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07139470
No phaseTaking people
A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.
Where
Hangzhou
Age
18 years and over
People
29
Run by
First Affiliated Hospital of Zhejiang University
See details and how to joinNCT06371274
No phaseTaking people
Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd
Where
Changsha
Age
18 years and over
People
200
Run by
Hunan Cancer Hospital
See details and how to joinNCT07073755
Phase 3Taking people
A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
Where
Shanghai
Age
18 years to 70 years
People
606
Run by
Fudan University
See details and how to joinNCT05862064
No phaseTaking people
Trop-2 Targeted PET Probes in Advanced TNBC
Where
Beijing
Age
18 years to 75 years
People
20
Run by
Peking University Cancer Hospital & Institute
See details and how to joinNCT07046455
Phase 2Taking people
Arsenous Acid for Refractory Triple-Negative Breast Cancer
Where
Guangzhou
Age
18 years to 75 years
People
12
Run by
Sun Yat-sen University
See details and how to joinNCT06678048
Phase 2Not yet taking people in China
Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer
Where
Tianjin
Age
18 years to 75 years
People
46
Run by
Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07005583
No phaseTaking people
Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration
Where
Beijing
Age
18 years to 75 years
People
51
Run by
Peking University Cancer Hospital & Institute
See details and how to joinNCT06991790
Phase 2Taking people
Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer
Where
Wuhan
Age
18 years to 70 years
People
27
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT06367088
Phase 2Taking people
A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer
Where
Tianjin
Age
18 years to 70 years
People
138
Run by
Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT06878625
Phase 2Taking people
The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer.
Where
Guangzhou
Age
18 years to 70 years
People
60
Run by
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT06851299